1. Home
  2. TMDX vs WLYB Comparison

TMDX vs WLYB Comparison

Compare TMDX & WLYB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TMDX
  • WLYB
  • Stock Information
  • Founded
  • TMDX 1998
  • WLYB 1807
  • Country
  • TMDX United States
  • WLYB United States
  • Employees
  • TMDX N/A
  • WLYB N/A
  • Industry
  • TMDX Biotechnology: Electromedical & Electrotherapeutic Apparatus
  • WLYB Books
  • Sector
  • TMDX Health Care
  • WLYB Consumer Discretionary
  • Exchange
  • TMDX Nasdaq
  • WLYB Nasdaq
  • Market Cap
  • TMDX 2.3B
  • WLYB 2.3B
  • IPO Year
  • TMDX 2019
  • WLYB N/A
  • Fundamental
  • Price
  • TMDX $127.12
  • WLYB $43.26
  • Analyst Decision
  • TMDX Buy
  • WLYB
  • Analyst Count
  • TMDX 10
  • WLYB 0
  • Target Price
  • TMDX $122.89
  • WLYB N/A
  • AVG Volume (30 Days)
  • TMDX 1.2M
  • WLYB 164.0
  • Earning Date
  • TMDX 05-08-2025
  • WLYB 06-17-2025
  • Dividend Yield
  • TMDX N/A
  • WLYB 3.57%
  • EPS Growth
  • TMDX N/A
  • WLYB N/A
  • EPS
  • TMDX 1.41
  • WLYB 0.75
  • Revenue
  • TMDX $488,227,000.00
  • WLYB $1,703,491,000.00
  • Revenue This Year
  • TMDX $32.58
  • WLYB N/A
  • Revenue Next Year
  • TMDX $21.65
  • WLYB $1.13
  • P/E Ratio
  • TMDX $90.23
  • WLYB $51.06
  • Revenue Growth
  • TMDX 64.43
  • WLYB N/A
  • 52 Week Low
  • TMDX $55.00
  • WLYB $35.68
  • 52 Week High
  • TMDX $177.37
  • WLYB $52.90
  • Technical
  • Relative Strength Index (RSI)
  • TMDX 76.52
  • WLYB 43.57
  • Support Level
  • TMDX $118.79
  • WLYB $39.54
  • Resistance Level
  • TMDX $130.48
  • WLYB $44.15
  • Average True Range (ATR)
  • TMDX 4.49
  • WLYB 0.00
  • MACD
  • TMDX -0.15
  • WLYB -0.08
  • Stochastic Oscillator
  • TMDX 83.53
  • WLYB 0.00

About TMDX TransMedics Group Inc.

TransMedics Group Inc is a commercial-stage medical technology company transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. It has developed the Organ Care System(OCS) to comprehensively address the limitations of cold storage. The OCS is a portable organ perfusion, optimization and monitoring system that utilizes technology to replicate near-physiologic conditions for donor organs outside of the human body. The Company has developed and is commercializing a proprietary system to preserve and deliver human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation.

About WLYB John Wiley & Sons Inc.

John Wiley & Sons Inc is one of the world's greatest publishers and a trusted leader in research and learning. Its industry-principal content, services, platforms, and knowledge networks are tailored to meet the evolving needs of its customers and partners, including researchers, students, instructors, professionals, institutions, and corporations. The company empowers knowledge-seekers to transform today's obstacles into tomorrow's brightest opportunities. For more than two centuries, the company has been delivering on its timeless mission to unlock human potential.

Share on Social Networks: